Merck KGaA Group has agreed to acquire Bio-Techne for $73 per share in cash
Merck KGaA Group has agreed to acquire Bio-Techne for $73 per share in cash.
Merck KGaA Group has agreed to acquire Bio-Techne for $73 per share in cash.
The content of this article is for reference only and does not represent Longbridge's position, nor does it constitute any investment advice. Investment involves risks, please invest cautiously.
